INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)
An International Dpen Access, Peer-reviewed, Refereed Journal

# QSAR Study for the treatment and prevention of thrombosis using Mer Specific tyrosine kinase inhibitors. 

Madhu Gupta ${ }^{1}$, Monika Sharma², Bhakti Kumari ${ }^{3}$, Seema Kohli ${ }^{4}$, Manish Rao Ambedkar ${ }^{5}$, Department of Chemistry, M.M.H. College, Ghaziabad, Uttar Pradesh, India ${ }^{1,2,3,4,5}$,

Abstract

Anti-platelet compounds are an important drug for cardiovascular diseases and for certain surgical procedures where a risk of stroke or thrombosis. Mer is a member of the TAM (Tyro3, Axl and Mer) receptor tyrosine kinase (RTK) subfamily with growth-arrest-specific-6Gas6) as one of the endogenous ligands. Currently, Mer has been shown to play important roles in regulating macrophage activity and platelet aggregation. The role of Mer kinase in regulating the second phase of platelet activation generates an opportunity to use Mer inhibitors for preventing thrombosis with diminished likelihood for bleeding as compared to current therapies. The QSAR tries to explain the observed variance in the biological effect of certain classes of compounds as a function of molecular changes caused by the substituents. These physiochemical descriptors which included parameters to account for hydrophobicity, electronic properties and steric effect are determined empirically or, more recently, by computational methods. QSAR methodologies save resources and expedite the process of the development of new molecules and drugs. In our works, we calculated many descriptors from the 43 molecular structures in literature 1 by the software Dragon, MLR Methods was used to select descriptor and set up linear model. Then we developed a new QSAR model to explore the $\mathrm{IC}_{50}$ of anti-thrombosis the compounds with diverse structures. The square of correlation coefficient $\left(R^{2}\right)$ for $\overline{b e s t}$ model with penta molecular descriptors after deletion of three compound is 0.9326 . The best model since the values $R=0.9657, R^{2}=0.9326, R^{2} A=0.9227, R^{2} c v=0.9325$ are the best as compared to all the models. The calculated $F$ value is greater than $F$ theoretical value, the value of standard error of estimate is the lowest, $\mathrm{SE}=0.5655$, PRESS $/$ SSY $=0.06743$ confirms that it is statistically significant and excellent model and it has been found to be having outstanding predictive power also. The present finding the based on QSAR are in excellent agreement with the result obtain by Linhao Xu et al.

Key words: QSAR, Anti-platelet compounds, Thrombosis using Mer, tyrosine kinase inhibitors.

## Introduction

Pathologic thrombus formation cause stroke or heart attack. Therefore, Anti-platelet compounds are an important drug for cardiovascular diseases and for certain surgical procedures where a risk of stroke or thrombosis. Mer is a member of the TAM (Tyro3, Axl and Mer) receptor tyrosine kinase (RTK) subfamily with growth-arrest-specific-6Gas6) as one of the endogenous ligands [1,2]. Currently, Mer has been shown to play important roles in regulating macrophage activity and platelet aggregation. The role of Mer kinase in regulating the second phase of platelet activation generates an opportunity to use Mer inhibitors for preventing thrombosis with diminished likelihood for bleeding as compared to current therapies.

## MATERIALS AND METHODS:

The QSAR (Quantitative structure activity relationship) tries to explain the observed variance in the biological effect of certain classes of compounds a function of molecular changes caused by the substituents. These physiochemical descriptors which included parameters to account for hydrophobicity, electronic properties and steric effect are determined empirically or, more recently, by computational methods [4]. QSAR methodologies save resources and expedite the process of the development of new molecules and drugs [5-7]. In our works, we calculated many descriptors from the 43 molecular structures in literature1 by the software Dragon, MLR Methods was used to select descriptor and set up linear model. Then we developed a new QSAR model to explore the $I C_{50}$ of anti-thrombosis the compounds with diverse structure.

## RESULTS AND DISCUSSION :

Table-1: Structural details and their activity use in present study.



5

0.067

6




10

0.0041


13


14

15

0.029


16



19

0.0063

20


22

0.0043


25



28


29

0.11

30


0.17

31


32





33







Table 2: Structural Details of Compounds with their activities and topological parameters used in the present study.

| Comp <br> No | IC50 $(\mu \mathrm{M})$ | IP1 | Jhetm | J | X2A | IP2 |
| ---: | :---: | :---: | ---: | ---: | ---: | :---: |
| 1 | 0.04 | 1 | 1.869 | 1.517 | 0.298 | 0 |
| 2 | 12.6 | 0 | 1.862 | 1.507 | 0.298 | 0 |
| 3 | 0.023 | 1 | 1.953 | 1.558 | 0.297 | 1 |
| 4 | 32 | 0 | 1.945 | 1.548 | 0.297 | 1 |
| 5 | 0.067 | 1 | 2.275 | 1.886 | 0.307 | 1 |
| 6 | 5.9 | 1 | 2.345 | 1.946 | 0.304 | 1 |
| 7 | 0.009 | 1 | 1.858 | 1.552 | 0.299 | 1 |
| 8 | 2.5 | 1 | 1.908 | 1.588 | 0.296 | 1 |


| 9 | 0.0084 | 1 | 1.842 | 1.551 | 0.302 | 1 |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 10 | 0.0041 | 1 | 1.522 | 1.273 | 0.293 | 1 |
| 11 | 0.013 | 1 | 1.861 | 1.552 | 0.299 | 1 |
| 12 | 0.008 | 1 | 1.854 | 1.552 | 0.299 | 1 |
| 13 | 0.23 | 1 | 1.923 | 1.539 | 0.303 | 1 |
| 14 | 0.015 | 1 | 1.921 | 1.538 | 0.297 | 1 |
| 15 | 0.029 | 1 | 1.946 | 1.561 | 0.297 | 1 |
| 16 | 0.039 | 1 | 1.972 | 1.587 | 0.295 | 1 |
| 17 | 0.014 | 1 | 1.585 | 1.273 | 0.293 | 1 |
| 18 | 0.0067 | 1 | 1.54 | 1.247 | 0.296 | 1 |
| 19 | 0.0063 | 1 | 1.711 | 1.285 | 0.292 | 1 |
| 20 | 0.014 | 1 | 1.851 | 1.51 | 0.301 | 1 |
| 21 | 0.0052 | 1 | 1.892 | 1.494 | 0.304 | 1 |
| 22 | 0.0043 | 1 | 1.541 | 1.24 | 0.293 | 1 |
| 23 | 0.0021 | 1 | 1.71 | 1.285 | 0.292 | 0 |
| 24 | 0.59 | 1 | 1.71 | 1.285 | 0.292 | 0 |
| 25 | 0.037 | 1 | 1.681 | 1.267 | 0.292 | 0 |
| 26 | 0.14 | 1 | 1.722 | 1.279 | 0.291 | 0 |
| 27 | 0.062 | 1 | 1.718 | 1.279 | 0.291 | 0 |
| 28 | 1 | 1 | 1.721 | 1.271 | 0.29 | 0 |
| 29 | 0.11 | 1 | 1.725 | 1.271 | 0.29 | 0 |
| 30 | 0.62 | 1 | 1.719 | 1.267 | 0.292 | 0 |
| 31 | 0.17 | 1 | 1.72 | 1.279 | 0.291 | 0 |
| 32 | 9.9 | 1 | 1.756 | 1.289 | 0.288 | 0 |
| 33 | 2.4 | 1 | 1.704 | 1.264 | 0.29 | 1 |
| 34 | 0.15 | 1 | 1.722 | 1.277 | 0.288 | 1 |
| 35 | 0.037 | 1 | 1.727 | 1.285 | 0.289 | 1 |
| 36 | 0.011 | 1 | 1.723 | 1.287 | 0.291 | 1 |
| 37 | 0.027 | 1 | 1.692 | 1.279 | 0.293 | 1 |
| 38 | 0.0073 | 1 | 1.476 | 1.116 | 0.287 | 1 |
| 39 | 0.059 | 1 | 1.713 | 1.285 | 0.292 | 1 |
| 40 | 0.024 | 1 | 1.737 | 1.295 | 0.294 | 1 |
| 41 | 0.047 | 1 | 1.505 | 1.137 | 0.288 | 1 |
| 42 | 0.18 | 1 | 1.737 | 1.295 | 0.294 | 1 |
| 43 | 0.12 | 1 | 1.499 | 1.121 | 0.29 | 1 |

Table 3: Correlation Matrix showing inter- correlation among all the parameters with the activity.

|  | $I C 50(\mu M)$ | IP1 | Jhetm | $J$ | $X 2 A$ | $I P 2$ |
| :--- | ---: | ---: | ---: | ---: | ---: | ---: |
| IC50 $(\mu \mathrm{M})$ | 1 |  |  |  |  |  |
| IP1 | -0.85858 | 1 |  |  |  |  |
| Jhetm | 0.238235 | -0.15881 | 1 |  |  |  |
| J | 0.210039 | -0.16793 | 0.952375 | 1 |  |  |
| X2A | 0.088171 | -0.13495 | 0.762843 | 0.869459 | 1 |  |
| IP2 | -0.05797 | 0.108787 | 0.119253 | 0.246989 | 0.3143 | 1 |

Table- 4: Regression Model

| Model No | Parameter Used | AI | B | SE | R | R2 | R2A | F Ratio | $\mathrm{Q}=\mathrm{r} / \mathrm{se}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | IP1 | -21.6993 ( $\pm 2.0236$ ) | 22.3000 | 2.7944 | 0.8586 | 0.7372 | 0.7308 | 114.9903 | 0.3073 |
| 41 | IP1 <br> JHETM | $\begin{gathered} -21.2798( \pm 2.0326) \\ 3.1516( \pm 2.4251) \end{gathered}$ | 16.3010 | 2.7712 | 0.8648 | 0.7478 | 0.7352 | 59.3057 | 0.3121 |
| 47 | IP1 <br> JHETM <br> J | $\begin{aligned} & -21.4239( \pm 2.0191) \\ & 12.6952( \pm 7.7880) \\ & -9.7215( \pm 7.5453) \end{aligned}$ | 12.9842 | 2.7486 | 0.8707 | 0.7581 | 0.7395 | 40.7429 | 0.3168 |
| 52 | IP1 JHETM X2A J | $\begin{aligned} & -21.3343( \pm 1.9741) \\ & 6.5452( \pm 8.4447) \\ & -318.8828( \pm 189.6345) \\ & -318.8828( \pm 10.7088) \end{aligned}$ | 99.6132 | 2.6864 | 0.8803 | 0.7749 | 0.7512 | 32.6961 | 0.3277 |
| 55 | IP1 <br> JHETM <br> J <br> X2A <br> IP2 | $\begin{aligned} & -21.6965( \pm 2.0009) \\ & 9.8653( \pm 9.0005) \\ & -0.2654( \pm 11.2247) \\ & -0.2654( \pm 189.5203) \\ & 9.8653( \pm 1.0398) \end{aligned}$ | $100.7374$ | 2.6824 | $0.8840$ | $0.7814$ | 0.7519 | 26.4570 | 0.3296 |

The Models are as follows-

## Mono Parametric

iC50 $=-21.6993( \pm 2.0236)$ IP1 +22.3000,
$\mathrm{N}=43, \mathrm{SE}=(2.7944), \mathrm{R}=(0.8586), \mathrm{R} 2=(0.7372), \mathrm{R} 2 \mathrm{~A}=(0.7308), \mathrm{F} R A T I O=(114.9903), \mathrm{Q}=(0.3073)$

## Bi Parametric

iC50 $=-21.2798( \pm 2.0326)$ IP1 $3.1516( \pm 2.4251)$ JHETM +16.3010,
$\mathrm{N}=43, \mathrm{SE}=(2.7712), \mathrm{R}=(0.8648), \mathrm{R} 2=(0.7478), \mathrm{R} 2 \mathrm{~A}=(0.7352), \mathrm{FRATIO}=(59.3057), \mathrm{Q}=(0.3121)$

## Tri Parametric

iC50 $=-21.4239( \pm 2.0191)$ IP1 $12.6952( \pm 7.7880)$ JHETM $-9.7215( \pm 7.5453) \mathrm{J}+12.9842$,
$\mathrm{N}=43, \mathrm{SE}=(2.7486), \mathrm{R}=(0.8707), \mathrm{R} 2=(0.7581), \mathrm{R} 2 \mathrm{~A}=(0.7395), \mathrm{FRATIO}=(40.7429), \mathrm{Q}=(0.3168)$

## Tetra Parametric

iC50 $=-21.3343( \pm 1.9741)$ IP1 $6.5452( \pm 8.4447)$ JHETM $-318.8828( \pm 189.6345) \mathrm{J}-318.8828( \pm 10.7088)$ X2A +99.6132 ,
$\mathrm{N}=43, \mathrm{SE}=(2.6864), \mathrm{R}=(0.8803), \mathrm{R} 2=(0.7749), \mathrm{R} 2 \mathrm{~A}=(0.7512), \mathrm{FRATIO}=(32.6961), \mathrm{Q}=(0.3277)$

## Penta Parametric

iC50 $=-21.6965( \pm 2.0009)$ IP1 $9.8653( \pm 9.0005)$ JHETM $-0.2654( \pm 11.2247)$ J -0.2654 ( $\pm 189.5203$ ) X2A $9.8653( \pm 1.0398)$ IP2 +100.7374,
$\mathrm{N}=43, \mathrm{SE}=(2.6824), \mathrm{R}=(0.8840), \mathrm{R} 2=(0.7814), \mathrm{R} 2 \mathrm{~A}=(0.7519), \mathrm{FRATIO}=(26.4570), \mathrm{Q}=(0.3296)$

Table- 5: Observed and Estimated Model -55 Topological Indices

| CompNo | Observed IC50( $\mu \mathrm{M}$ ) | Predicted IC50( $\mu \mathrm{M}$ ) | Residuals |
| :---: | :---: | :---: | :---: |
| 1 | 0.04 | -0.446145615 | 0.486145615 |
| 2 | 12.6 | 21.18399885 | -8.583998853 |
| 3 | 0.023 | 1.795722029 | -1.772722029 |
| 4 | 32 | 23.41600115 | 8.583998853 |
| 5 | 0.067 | 1.612746724 | -1.545746724 |
| 6 | 5.9 | 3.269171979 | 2.630828021 |
| 7 | 0.009 | 0.205590762 | -0.196590762 |
| 8 | 2.5 | 1.671077899 | 0.828922101 |
| 9 | 0.0084 | -0.93376243 | 0.94216243 |
| 10 | 0.0041 | -1.07158255 | 1.07568255 |
| 11 | 0.013 | 0.23518681 | -0.22218681 |
| 12 | 0.008 | 0.166129366 | -0.158129366 |
| 13 | 0.23 | -0.458742379 | 0.688742379 |
| 14 | 0.015 | 1.485338244 | -1.470338244 |
| 15 | 0.029 | 1.725868478 | -1.696868478 |
| 16 | 0.039 | 2.62998327 | -2.59098327 |
| 17 | 0.014 | -0.450065556 | 0.464065556 |
| 18 | 0.0067 | -1.86887964 | 1.87557964 |
| 19 | 0.0063 | 1.117041659 | -1.110741659 |
| 20 | 0.014 | -0.506836488 | 0.520836488 |
| 21 | 0.0052 | -1.079884241 | 1.085084241 |
| 22 | 0.0043 | -0.87538373 | 0.87968373 |
| 23 | 0.0021 | 0.010375508 | -0.008275508 |
| 24 | 0.59 | 0.010375508 | 0.579624492 |
| 25 | 0.037 | -0.270942968 | 0.307942968 |
| 26 | 0.14 | 0.457609572 | -0.317609572 |
| 27 | 0.062 | 0.418148176 | -0.356148176 |
| 28 | 1 | 0.777124836 | 0.222875164 |
| 29 | 0.11 | 0.816586233 | $-0.706586233$ |
| 30 | 0.62 | 0.103940298 | 0.516059702 |
| 31 | 0.17 | 0.437878874 | -0.267878874 |
| 32 | 9.9 | 1.772150725 | 8.127849275 |
| 33 | 2.4 | 1.708072288 | 0.691927712 |
| 34 | 0.15 | 2.536714088 | -2.386714088 |
| 35 | 0.037 | 2.256660221 | -2.219660221 |
| 36 | 0.011 | 1.562152768 | -1.551152768 |
| 37 | 0.027 | 0.603934583 | -0.576934583 |
| 38 | 0.0073 | 0.479820324 | -0.472520324 |
| 39 | 0.059 | 1.136772357 | -1.077772357 |
| 40 | 0.024 | 0.716371726 | -0.692371726 |
| 41 | 0.047 | 0.433085034 | -0.386085034 |
| 42 | 0.18 | 0.716371726 | -0.536371726 |
| 43 | 0.12 | -0.276376469 | 0.396376469 |


| IJCRT2201163 | International Journal of Creative Research Thoughts (IJCRT) www.ijcrt.org | b303 |
| :--- | :--- | :--- | :--- |

Figure- 1


The cross validated parameters have been calculated for these models and recorded in table 7 on the basis of cross validated parameters The penta parametric model discussed above has been formed to be the best model.

Table-6: Cross validation of Topological Indices

| Model No | Parameter Used | press | Ssy | Press/SSY | $\mathrm{R}^{2} \mathrm{CV}$ | PSE | Spress |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | IP1 | 320.1539 | 1218.07 | 0.2628 | 0.7372 | 2.7286 | 2.7944 |
| 41 | IP1 <br> JHETM | 307.1837 | 1218.07 | 0.2522 | 0.7478 | 2.6728 | 2.7712 |
| 47 | IP1 <br> JHETM <br> J | 294.6422 | 1218.07 | 0.2419 | 0.7581 | $2.6177$ | 2.7486 |
| 52 | IP1 <br> JHETM <br> X2A <br> J | 274.2358 | $1218.07$ | 0.2251 | $0.7749$ | $2.5254$ | $2.6864$ |
| 55 | IP1 <br> JHETM <br> J <br> X2A <br> IP2 | $266.2293$ | 1218.07 | $0.2186$ | 0.7814 | $2.4882$ | $2.6824$ |

Among all the penta parametric models listed in table 5 models $1,41,47,52$ and 55 gave quite improved results. The significance and quality of these models was checked on the basis of the values of " R ", " R2", "R2A ", quality factor "Q", standard error of estimate "SE", " R2 C2V", "PSE", and PRESS/SSY ratio of these equations. The squared correlation coefficient (R2) is a measure of the fit of the regression model correspondingly, it represents the part of variation in the observed data explained by the model .Study of these models shows that while carrying out the tetra parametric regression analysis, R2A goes on increasing while SE goes on decreasing and it means that statistically the quality of models goes on increasing. All the equations have higher $Q$ value. $Q$ is the quality factor estimated to determine the predictive value of the model.

Using model no 55 that is best penta parametric model [table -6] we have estimated pIC50 values. The residual values that is difference between estimated and observed pIC50 values of the compounds no 4, 6,and 32 is much higher than other compounds. These compounds have been taken as outlier. Their fore the entire exercise was repeated and new models have been obtain which are reported in table 8 . Again plc50 value of the compound have been estimated using model no 55 , of table 8.

Table-7: Topological Indices - Regression of After Deletion of Compound no - [ 4, 6, 32 ]

| Model No | Parameter Used | AI | B | SE | R | R2 | R2A | F Ratio | $\mathrm{Q}=\mathrm{r} / \mathrm{se}$ |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | IP1 | -12.3736 ( $\pm 0.5679$ ) | 12.6000 | 0.5608 | 0.9622 | 0.9259 | 0.9239 | 474.6829 | 1.7158 |
| 41 | IP1 <br> JHTEM | $\begin{aligned} & -12.3528( \pm 0.5779) \\ & 0.1966( \pm 0.5779) \end{aligned}$ | 12.2340 | 0.5674 | 0.9623 | 0.9261 | 0.9221 | 231.8759 | 1.6960 |
| 47 | IP1 JHTEM J | $\begin{gathered} -12.3879( \pm 0.5848) \\ 1.2483( \pm 1.6908) \\ -1.0693( \pm 1.6140) \end{gathered}$ | 11.8872 | 0.5718 | 0.9628 | 0.9270 | 0.9209 | 152.3863 | 1.6838 |
| 52 | IP1 JHTEM J X2A | $\begin{aligned} & -12.3901( \pm 0.5700) \\ & 0.1457( \pm 1.7711) \\ & 1.6556( \pm 2.2458) \\ & 1.6556( \pm 41.2344) \end{aligned}$ | 30.7254 | $0.5573$ | 0.9657 | $0.9326$ | $0.9249$ | 121.0146 | 1.7328 |
| 55 | IP1 <br> JHTEM <br> J <br> X2A <br> IP2 | $\begin{aligned} & -12.3877( \pm 0.6146) \\ & 0.1375( \pm 1.9354) \\ & 1.6643( \pm 2.4036) \\ & 1.6643( \pm 41.8588) \\ & 0.1375( \pm 0.2343) \end{aligned}$ | $30.7229$ | 0.5655 | 0.9657 | 0.9326 | 0.9227 | $94.0460$ | 1.7077 |

The Model of training is as follow
Mono Parametric
iC50 $=-12.3736( \pm 0.5679)$ IP1 +12.6000,
$\mathrm{N}=40, \mathrm{SE}=(0.5608), \mathrm{R}=(0.9622), \mathrm{R} 2=(0.9259), \mathrm{R} 2 \mathrm{~A}=(0.9239), \mathrm{FRATIO}=(474.6829), \mathrm{Q}=(1.7158)$

Bi Parametric
iC50 $=-12.3528( \pm 0.5779)$ IP1 $0.1966( \pm 0.5779)$ JHETM +12.2340 ,
$N=40, S E=(0.5674), R=(0.9623), R 2=(0.9261), R 2 A=(0.9221), F R A T I O=(231.8759), Q=(1.6960)$

Tri Parametric
iC50 $=-12.3879( \pm 0.5848)$ IP1 1.2483 ( $\pm 1.6908$ ) JHETM $-1.0693( \pm 1.6140) \mathrm{J}+11.8872$,
$N=40, S E=(0.5718), R=(0.9628), R 2=(0.9270), R 2 A=(0.9209), F R A T I O=(152.3863), Q=(1.6838)$

Tetra Parametric
iC50 $=-12.3901( \pm 0.5700)$ IP1 $0.1457( \pm 1.7711)$ JHETM $1.6556( \pm 2.2458)$ J $1.6556( \pm 41.2344)$ X2A +30.7254 ,
$\mathrm{N}=40, \mathrm{SE}=(0.5573), \mathrm{R}=(0.9657), \mathrm{R} 2=(0.9326), \mathrm{R} 2 \mathrm{~A}=(0.9249), \mathrm{FRATIO}=(121.0146), \mathrm{Q}=(1.7328)$

Penta Parametric
iC50 $=-12.3877( \pm 0.6146)$ IP1 $0.1375( \pm 1.9354)$ JHETM $1.6643( \pm 2.4036) \mathrm{J} 1.6643( \pm 41.8588)$ X2A $0.1375( \pm 0.2343)$ IP2 +30.7229,
$\mathrm{N}=40, \mathrm{SE}=(0.5655), \mathrm{R}=(0.9657), \mathrm{R} 2=(0.9326), \mathrm{R} 2 \mathrm{~A}=(0.9227), \mathrm{FRATIO}=(94.0460), \mathrm{Q}=(1.7077)$

Table-8 Topological Indices- Observed and Estimated of After Deletion of Compound no.[ 4, 6, 32 ]

| Sn | Observed $\text { IC50( } \mu \mathrm{M} \text { ) }$ | Predicted $\text { IC50( } \mu \mathrm{M})$ | Residuals |
| :---: | :---: | :---: | :---: |
| 1 | 0.04 | 0.229887 | -0.18989 |
| 2 | 12.6 | 12.6 | -1.4E-14 |
| 3 | 0.023 | 0.377106 | -0.35411 |
| 4 | 0.067 | 0.266361 | -0.19936 |
| 5 | 0.009 | 0.213874 | -0.20487 |
| 6 | 2.5 | 0.490936 | $2.009064$ |
| 7 | 0.0084 | $-0.00026$ | 0.008662 |
| 8 | 0.0041 | 0.12388 | -0.11978 |
| 9 | 0.013 | 0.214287 | -0.20129 |
| 10 | 0.008 | 0.213324 | -0.20532 |
| 11 | 0.23 | -0.07918 | 0.309185 |
| 12 | 0.015 | 0.33942 | -0.32442 |
| 13 | 0.029 | 0.381136 | -0.35214 |
| 14 | 0.039 | 0.568164 | -0.52916 |
|  |  |  |  |
| 15 | 0.014 | 0.132544 | -0.11854 |
| 16 | 0.0067 | -0.12719 | 0.133887 |
| 17 | 0.0063 | 0.239934 | -0.23363 |
| 18 | 0.014 | 0.002831 | 0.011169 |
| 19 | 0.0052 | -0.22843 | 0.23363 |
| 20 | 0.0043 | 0.071572 | -0.06727 |
| 21 | 0.0021 | 0.242455 | -0.24036 |
| 22 | 0.59 | 0.242455 | 0.347545 |
| 23 | 0.037 | 0.20851 | -0.17151 |
| 24 | 0.14 | 0.304211 | -0.16421 |
| 25 | 0.062 | 0.303661 | -0.24166 |
| 26 | 1 | 0.36085 | 0.63915 |
| 27 | 0.11 | 0.3614 | -0.2514 |
| 28 | 0.62 | 0.213736 | 0.406264 |
| 29 | 0.17 | 0.303936 | -0.13394 |
| 30 | 2.4 | 0.344204 | 2.055796 |
| 31 | 0.15 | 0.508496 | -0.3585 |
| 32 | 0.037 | 0.452407 | -0.41541 |
| 33 | 0.011 | 0.315004 | -0.304 |
| 34 | 0.027 | 0.157245 | -0.13025 |
| 35 | 0.0073 | 0.276809 | -0.26951 |


| 36 | 0.059 | 0.240209 | -0.18121 |
| :---: | :---: | :---: | :---: |
| 37 | 0.024 | 0.119971 | -0.09597 |
| 38 | 0.047 | 0.245656 | -0.19866 |
| 39 | 0.18 | 0.119971 | 0.060029 |
| 40 | 0.12 | 0.078021 | 0.041979 |

Figure 2


Table-9: Topological Indices- Crossed validation

| Model No | Parameter Used | Press | SSY | Press/SSY | $\mathrm{R}^{2} \mathrm{CV}$ | PSE | Spress |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| 1 | IP1 | 11.95025 | 161.2287 | 0.07412 | 0.92588 | 0.546586 | 0.560785 |
| 41 | IP1 <br> JHTEM | $11.91301$ | 161.2287 | 0.073889 | 0.926111 | 0.545734 | 0.567427 |
| 48 | IP1 <br> JHTEM | $11.7695$ | 161.2287 | $0.072999$ | 0.927001 | $0.542437$ | $0.571778$ |
| 53 | IP1 <br> JHEM <br> J $\mathrm{X} 2 \mathrm{~A}$ | $10.87162$ | $161.2287$ | $0.06743$ | 0.93257 | $0.521335$ | $0.557331$ |
| 56 | IP1 <br> JHETM <br> J <br> X2A <br> IP2 | 10.87157 | 161.2287 | 0.06743 | $0.93257$ | 0.521334 | 0.565466 |

PRESS (predicted residual sum of squares) appears to be the most important cross validation parameters accounting for good estimate of the real predictive error of the models. In case its value is less than SSY ( sum of the square of all response value ), it will mean that the predictive power of the model is good and is not based upon chance therefore, can be considered statistically significant

To be a reasonable QSAR model , PRESS/SSY should be smaller than 0.400 . In our case, the ratio PRESS/SSY ranges between 0.07410.0674 indicating that all proposed models (equations $1,41,47,52$ and 55 ) are reliable. The PSE and SPRESS are good parameters to discuss the uncertainty in prediction. The lower the value of these parameters, the better will be the predictive ability of the model. The indication of the performance of the model is obtained from R2 CV (the overall predictive ability) higher R2 CV shows that the model is good. In order to examine the relative potential of models, predictive correlation coefficient (R2 pred) were estimated by plotting graphs between observed and calculated ic50 values obtained with the help of eqn 55 . The comparison between observed and predicted activities is listed in Table- 9. Such correlations are shown in figure 2. From the fig 2, R2 pred values obtained for equation 55 is 0.9326 is fairly high indicating the good quality of models.

Amongst all these statistically significant five models discussed above model 55 is the best model since the values $R=0.9657, R 2=$ $0.9326, \mathrm{R} 2 \mathrm{~A}=0.9227, \mathrm{R} 2 \mathrm{cv}=0.9325$ are the best as compared to all the models. The calculated F value is greater than F theoretical value , the value of standard error of estimate is the lowest, $\mathrm{SE}=0.5655$, $\mathrm{PRESS} / \mathrm{SSY}=0.06743$ confirms that it is statistically significant and excellent model and it has been found to be having outstanding predictive power also.

The generated QSAR model was employed to predicted ic50 activities of the test (Prediction) molecules and the outcome is displayed in table 8-10 the predictive power is also shown in the figure 3.

## Conclusion

On the basis of data and subsequent discussion presented in this section it may be suggested that in future designing of this class of drug with reference to their activity IC50 the following points may be kept in mind.
(1) Jhet $M, J, X 2$, and IP2 has positive coefficient and IP1 has positive coefficient. The high value of Jhet $M, J, X 2$, and IP2 and low value of IP1 suggesting that these topological parameters are suitable for the modeling of IC50.
(2) The compound no 2 found to be most potent drug. It is an excellent agreement with observed iC50 (observed and predicated and ic50 values are both 12.6 )
(3) IP1 favor increases the potency of the drug.
(4) The present finding the based on OSAR are in excellent agreement with the result obtain by Linhao Xu et al

References:
[1] dx.doi.org/10.1021/jm4013888 | J. Med. Chem.2013, 56:9693-970
[2] Laurance S, Lemarie CA, Blostein MD. Growth Arrest-Specific Gene 6 (gas6) and Vascular Hemostasis. Adv Nutr, 2012, 3(2):196-203.
[3] Fujita T. Qsar and Drug Design: New Development and Applications, Elsevier, Amsterdam, Netherlands, 1995, 1:413-450.
[4] Sahu V, Sharma P, Kumar A. Synthesis and QSAR modeling of 1-[3-methyl-2-(aryldiazenyl)-2H-aziren-2-yl]ethanones as potential antibacterial agents. Med.Chem. Res., 2013, 22(5):24762485.
[5] Bhadoriya KS, Kumawat NK, Bhavthankar SV, et al. Exploring 2D and 3D QSARs of benzimidazole derivatives as transient receptor potential melastatin 8 (TRPM8) antagonists using MLR and kNN-MFA methodology, J. Saudi Chem. Soc., 2012, 22:13-23.
[6] Bhadoriya KS, Sharma MC, Jain SV.Pharmacophore modeling and atom-based 3D-QSAR studies on amino derivatives of indole as potent isoprenylcysteine carboxyl methyltransferase (Icmt) inhibitors, J. Mol. Struc., 2014, 11:222-228.
[7] Bhadoriya KS, Sharma MC, Jain SV, et al. QSAR Studies of Fused 5, 6-Bicyclic Heterocycles as Y -Secretase Modulators, J. Pharm. Res., 2012, 5(8): 4127-4132.]

